{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-006408","form_type":"8-K","ticker":"VNOV","cik":"0001699709","company_name":"VitaNova Life Sciences Corp","filed_at":"2023-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.901707+00:00","generated_at":"2026-06-10T17:41:49.797569+00:00","sec_items":["5.01","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Yijia Group founder/CEO Xianchang Ma dies; heir gets 86.3% control; new CEO appointed","bullets":["Founder and sole director Xianchang Ma passed away on August 3, 2023.","On Sept 12, 2023, heir Caihong Qu acquired 5,066,250 shares (86.3% of outstanding) at $0 consideration, gaining control.","Effective Sept 13, 2023, board comprises Qiuping Lu and Ruiming Zhou; Lu appointed CEO, President, and CFO.","Ms. Lu previously served as CEO and CFO of China Herb Group Holdings from 2014 to 2019.","Mr. Zhou has been a director at Shandong Tengjunxiang Biotechnology Co. since June 2017."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-006408","json":"https://secwatch.observer/filing/0001683168-23-006408.json","markdown":"https://secwatch.observer/filing/0001683168-23-006408.md","text":"https://secwatch.observer/filing/0001683168-23-006408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/yijia_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T17:41:49.797569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41101b5d86","claim":"Xianchang Ma departed as Chief Executive Officer, President, Chief Financial Officer and Director at VitaNova Life Sciences Corp.","evidence_excerpt":"Mr. Xianchang Ma, previously the Chief Executive Officer, President, Chief Financial Officer and Director of the Company, passed away on August 3, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"passed away"},{"label":"Role","value":"Chief Executive Officer, President, Chief Financial Officer and Director"}],"fact_type":"executive_change"},{"claim_id":"88e06ef203","claim":"Qiuping Lu was appointed as Chief Executive Officer, President, Chief Financial Officer at VitaNova Life Sciences Corp.","evidence_excerpt":"On September 13, 2023, the Board resolved to appoint Ms. Qiuping Lu as the Chief Executive Officer, President, Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, President, Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"975ae45d16","claim":"Ruiming Zhou was appointed as Director at VitaNova Life Sciences Corp.","evidence_excerpt":"On September 13, 2023, the majority shareholder inducted Ms. Qiuping Lu, and Mr. Ruiming Zhou to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"inducted"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ab31b17d0f","claim":"Qiuping Lu was appointed as Director at VitaNova Life Sciences Corp.","evidence_excerpt":"On September 13, 2023, the majority shareholder inducted Ms. Qiuping Lu, and Mr. Ruiming Zhou to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"inducted"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6090fcff3f02d45aa9d49cea2237c9d37839cbc3","claim":"VitaNova Life Sciences Corp underwent a change of control involving Ms. Caihong Qu for $0 (closed 2023-09-12).","evidence_excerpt":"Ms. Caihong Qu, Mr. Xianchang Ma's sole heir, was allocated 5,066,250 shares of the Company's common stock at a consideration of $0.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm","confidence":0.7,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Ms. Caihong Qu"},{"label":"Consideration","value":"$0"},{"label":"Closing","value":"2023-09-12"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}